Detalles de la búsqueda
1.
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 402(10403): 705-719, 2023 08 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37385278
2.
Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1-4 trials.
Diabetes Obes Metab
; 26(7): 2945-2955, 2024 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-38698650
3.
Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses.
Diabetes Obes Metab
; 25(2): 468-478, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36200477
4.
A model-based approach to predict individual weight loss with semaglutide in people with overweight or obesity.
Diabetes Obes Metab
; 25(11): 3171-3180, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37424165
5.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
Lancet
; 397(10286): 1736-1748, 2021 05 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33894838
6.
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Lancet
; 398(10317): 2160-2172, 2021 12 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34798060
7.
Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.
Diabetes Obes Metab
; 24(1): 94-105, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34514682
8.
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
JAMA
; 327(2): 138-150, 2022 01 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35015037
9.
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
JAMA
; 325(14): 1414-1425, 2021 04 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33755728
10.
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
JAMA
; 325(14): 1403-1413, 2021 04 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-33625476
11.
Changes in weight control behaviors and hedonic hunger in a commercial weight management program adapted for individuals with type 2 diabetes.
Int J Obes (Lond)
; 44(5): 990-998, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31949295
12.
Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials.
EClinicalMedicine
; 55: 101737, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36467859
13.
Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program.
Postgrad Med
; 134(sup1): 28-36, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36691307
14.
Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice.
Postgrad Med
; 134(1): 14-19, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34775881
15.
A Systematic Review of Dietary Supplements and Alternative Therapies for Weight Loss.
Obesity (Silver Spring)
; 29(7): 1102-1113, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34159755
16.
Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial.
Obes Facts
; 13(6): 572-583, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33197917
17.
Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial.
Obesity (Silver Spring)
; 28(3): 529-536, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32090517
18.
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5.
Obesity (Silver Spring)
; 28(6): 1050-1061, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32441473
19.
Weight History in Clinical Practice: The State of the Science and Future Directions.
Obesity (Silver Spring)
; 28(1): 9-17, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31858735
20.
Radioimmunoassay and tandem mass spectrometry measurement of bedtime salivary cortisol levels: a comparison of assays to establish hypercortisolism.
J Clin Endocrinol Metab
; 92(8): 3102-7, 2007 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-17550962